SCHEMBL13049691

SCHEMBL13049691

OCc1cccc(-c2oc3ccccc3c2CO)c1

nearest known ligand 0.43

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
▸ MEN1 O00255 6/20 0.43
▸ KMT2A Q03164 6/20 0.43
▸ KDM4E B2RXH2 4/20 0.43
▸ CYP3A4 P08684 4/20 0.43
▸ CYP2D6 P10635 3/20 0.43
▸ MAPT P10636 3/20 0.43
▸ CYP2C9 P11712 3/20 0.43
▸ CYP2C19 P33261 3/20 0.43
▸ HPGD P15428 2/20 0.43
▸ HSD17B10 Q99714 2/20 0.43
▸ ALDH1A1 P00352 1/20 0.43
▸ ATM Q13315 2/20 0.42
▸ RCE1 Q9Y256 2/20 0.42
▸ L3MBTL1 Q9Y468 1/20 0.42
▸ PRKCI P41743 1/20 0.41
▸ TP53 P04637 3/20 0.39
▸ MAPK1 P28482 3/20 0.39
▸ ALOX12 P18054 2/20 0.39
▸ TSHR P16473 1/20 0.39
▸ TDP1 Q9NUW8 1/20 0.39

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL2962849 0.84 KMT2A (0.53) MEN1KMT2AKDM4ECYP3A4MAPT
SCHEMBL13049693 0.84 MAPT (0.48) MEN1KMT2AKDM4ECYP3A4CYP2D6
SCHEMBL13049690 0.84 MEN1 (0.60) MEN1KMT2AKDM4ECYP3A4CYP2D6
SCHEMBL13049706 0.83 PTPN1 (0.45) MEN1KMT2AKDM4ECYP3A4HPGD
SCHEMBL13049687 0.80 KMO (0.47) MEN1KMT2AKDM4ECYP3A4CYP2D6
SCHEMBL13049762 0.80 MEN1 (0.43) MEN1KMT2AKDM4ECYP3A4CYP2D6
SCHEMBL13049766 0.78 MAPT (0.49) MEN1KMT2AKDM4EMAPTALDH1A1
SCHEMBL13049702 0.75 MEN1 (0.47) MEN1KMT2AKDM4ECYP3A4CYP2D6
SCHEMBL13049689 0.75 MEN1 (0.47) MEN1KMT2AKDM4ECYP3A4CYP2D6
SCHEMBL13049701 0.75 LMNA (0.57) MEN1KMT2AKDM4ECYP3A4MAPT

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 9 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
US-7837981-B2 Methods for imaging soluble A-beta GENERAL ELECTRIC COMPANY (US) 2010-11-23 — — US disclosed
US-7837981-B2 Methods for imaging soluble A-beta GENERAL ELECTRIC COMPANY (US) 2010-11-23 — — US disclosed
EP-1631561-B1 COMPOSITIONS AND METHODS FOR NON-INVASIVE IMAGING OF SOLUBLE BETA-AMYLOID GEN ELECTRIC (US) 2010-08-18 — — EP disclosed
US-7727511-B2 Agents for imaging soluble a-beta GENERAL ELECTRIC COMPANY (US) 2010-06-01 — — US disclosed
US-7727511-B2 Agents for imaging soluble a-beta GENERAL ELECTRIC COMPANY (US) 2010-06-01 — — US disclosed
US-20070189967-A1 AGENTS FOR IMAGING SOLUBLE A-BETA GENERAL ELECTRIC COMPANY (US) 2007-08-16 — — US disclosed
US-20070189967-A1 AGENTS FOR IMAGING SOLUBLE A-BETA GENERAL ELECTRIC COMPANY (US) 2007-08-16 — — US disclosed
US-20070140960-A1 METHODS FOR IMAGING SOLUBLE A-BETA GENERAL ELECTRIC COMPANY (US) 2007-06-21 — — US disclosed
US-20070140960-A1 METHODS FOR IMAGING SOLUBLE A-BETA GENERAL ELECTRIC COMPANY (US) 2007-06-21 — — US disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20070140960-A1 METHODS FOR IMAGING SOLUBLE A-BETA APBA1, APP, FABP7 MEN1 1513/4885KMT2A 4355/4885KDM4E 4759/4885
US-20070189967-A1 AGENTS FOR IMAGING SOLUBLE A-BETA APBA1, APP, FABP7 MEN1 1254/4885KMT2A 4536/4885KDM4E 4807/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.

Send feedback